Dr. Reddy Laboratories RDY
-
Dr . Reddy's Laboratories' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Dr. Reddy 's Laboratories ( RDY ) Q4 2012 Earnings Call May 11, 2012 9:00 am ET Executives Kedar ..... Executive Vice President and Member of Management Council Kallam Satish Reddy - Managing Director, Chief Operating Officer, Executive Director …
-
Dr. Reddy's U.S. and Emerging Market Growth Continues to Outshine Lackluster European Results
… adjust our fair value estimate for Dr. Reddy 's Laboratories RDY after the company's reported fourth ..... million intangible impairment from Dr. Reddy 's struggling European operations. Despite ongoing weakness in Europe, Dr. Reddy continues to post impressive results in …
-
Dr . Reddy Laboratories , Ltd. RDY Q4 2012 Earnings Call Transcript
… and welcome to the Q4 FY '12 Earnings Conference Call of Dr. Reddy 's Laboratories Limited. As a reminder, all participant lines ..... evening to all, and thank you for joining us today for Dr. Reddy 's earnings call for the quarter and full year ended March …
-
New Morningstar Analyst Report - Perrigo Company
… recent OTC launch of Allegra, but recent strides from emerging market generic drug companies in the OTC segment, such as Dr. Reddy 's Laboratories RDY , may erase some of Perrigo's gains in future expected OTC drug launches. Management has also done a good job expanding …
-
Perrigo's Prescription Segment Offsets Margin Pressure
… operating margin nearly 100 basis points from the year-ago period. Perrigo has seen particularly tough competition from Dr. Reddy RDY in the gastrointestinal OTC segment. While new product launches over the next six months, including generic Clarinex, Prevacid …
-
Dr . Reddy's Laboratories' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Dr. Reddy 's Laboratories ( RDY ) Q3 2012 Earnings Call February 03, 2012 8:00 am ET Executives ..... Senior Vice President and Member of Management Council Kallam Satish Reddy - Managing Director, Chief Operating Officer, Executive Director …
-
Dr. Reddy's Revenue Surges on Generic Zyprexa
Dr. Reddy 's Laboratories RDY reported solid third-quarter results ..... exclusivity period for Zyprexa expires. Dr. Reddy received first-to-file status for ..... status on the other formulations. Dr. Reddy also reported strong results in its …
-
Dr . Reddy Laboratories , Ltd. RDY Q3 2012 Earnings Call Transcript
… and welcome to the Q3 FY '12 Earnings Conference Call of Dr. Reddy 's Laboratories Limited. As a reminder, all participant lines ..... recorded. Good morning and good evening to all. Welcome to Dr. Reddy 's Q3 FY '12 earnings conference call for the quarter ended …
-
Morgan Stanley names Dr. Reddy's Labs ([[ RDY ]] -0.9%) a Long Research Tactical Idea with an eye on the firm's plans to launch a generic version of Lipitor later this year.
Morgan Stanley names Dr. Reddy 's Labs ( RDY -0.9% ) a Long Research Tactical Idea with an eye on the firm's plans to launch a generic version of Lipitor later this year. Post your comment!
-
Dr. Reddy's : Underperformer In The U.S., Outperformer In India
By Richard Bloch : I bought shares of Dr. Reddy ’s Laboratories ( RDY ) a couple of years ago. This Indian pharmaceuticals company mainly produces generic drugs, plus a few proprietary medications …